Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy

BACKGROUND: Recently, the combination of venetoclax plus a hypomethylating agent (HMA; azacitidine ordecitabine) or low‐dose cytarabine (LDAC) showed promise in Phase III trials in previously untreated AML. In France at the time of this study, venetoclax was not yet approved for AML and there were t...

Descripción completa

Detalles Bibliográficos
Autores principales: Laloi, Louise, Billotey, Natacha Chaumard, Dumas, Pierre‐Yves, Paul, Franciane, Villate, Alban, Simand, Célestine, Fornecker, Luc, Puisset, Florent, Bertoli, Sarah, Simonet, Marion Boissard, Laribi, Kamel, Houyou, Dyhia, Santagostino, Alberto, Michel, Claire, Guepin, Gabrielle Roth, Guerineau, Elodie, Tabrizi, Reza, Hunault, Mathilde, Giltat, Aurélien, Kaphan, Eléonore, Bulabois, Claude, Cartet, Elodie, Rocher, Clément, Lachenal, Florence, Morisset, Stéphane, Récher, Christian, Pigneux, Arnaud, Belhabri, Amine, Michallet, Mauricette, Michallet, Anne‐Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
BRIEF COMMUNICATION
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067034/
https://www.ncbi.nlm.nih.gov/pubmed/36482507
http://dx.doi.org/10.1002/cam4.5459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067034/
https://www.ncbi.nlm.nih.gov/pubmed/36482507
http://dx.doi.org/10.1002/cam4.5459

Ejemplares similares